Industry
Asset Management
John Hancock Premium Dividend Fund is a closed ended equity mutual fund launched and managed by John Hancock Investment Management LLC. It is co-managed by John Hancock Asset Management. The fund invests in the public equity markets of the United States. It seeks to invest in stocks of companies operating across diversified sectors, with an emphasis on the utilities sector. The fund primarily invests in dividend paying preferred stocks and common stocks of companies. It benchmarks the performance of its portfolio against a composite benchmark comprised of 70% Bank of America Merrill Lynch Preferred Stock DRD Eligible Index and 30% S&P 500 Utilities Index. The fund was formerly known as John Hancock Patriot Premium Dividend Fund II. John Hancock Premium Dividend Fund was formed on December 21, 1989 and is domiciled in the United States.
Loading...
Open
12.97
Mkt cap
641M
Volume
91K
High
13.10
P/E Ratio
12.54
52-wk high
13.55
Low
12.95
Div yield
0.08
52-wk low
10.36

During Friday's session, 157 stocks hit new 52-week lows. Among the notable companies were Corteva, American Rebel Holdings, Mullen Automotive, and BNY Mellon Strategic. The stocks that created new 52-week lows on Friday included Avangrid, SolarEdge Technologies, Etsy, UGI, Concentrix, Hawaiian Electric Indus, Equity Commonwealth, Forward Air, Cracker Barrel Old, Petco Health and Wellness, JinkoSolar Holding Co, Olaplex Hldgs, Frontier Group Holdings, Impinj, Safehold, Monro, 3D Sys, TDCX, Everbridge, Silk Road Medical, Cassava Sciences, 23andMe Holding, Wolverine World Wide, Avidity Biosciences, Boston Omaha, John Hancock Premium Div, BioLife Solns, Seres Therapeutics, American Well, Materialise, BNY Mellon Strategic, Southland Holdings, Funko, Fate Therapeutics, Citizens Financial Servs, American Lithium, Emergent BioSolutions, PetMed Express, Sutro Biopharma, Hippo Holdings, Largo, Omega Therapeutics, System1, Benson Hill, Eaton Vance Municipal, Vor Biopharma, Star Hldgs, Origin Mat, Joint, NanoString Technologies, Codexis, ContextLogic, Akoustis Technologies, Cano Health, GeneDx Hldgs, Electrovaya, Kezar Life Sciences, ProPhase Labs, Alaunos Therapeutics, Chimerix, Electriq Power Holdings, DZS, Streamline Health Solns, Eargo, Intercure, Prime Number Acquisition, REE Automotive, TD Hldgs, Carmell Therapeutics, Neuronetics, Kaixin Auto Hldgs, Crown Crafts, Airgain, Ohmyhome, Singular Genomics Sys, First Seacoast Bancorp, Sarcos Technology, Coya Therapeutics, Otonomo Technologies, CareCloud, Aterian, PAVmed, Orgenesis, CalAmp, Imperial Ptrl, Fitell, LQR House, Iridex, OMNIQ, Safeguard Scientifics, Lichen China, Origin Agritech, Atreca, Sunlight Finl Hldgs, Yunji, MediaCo Holding, Trio Petroleum, Cineverse, Lucy Scientific Discovery, Remark Hldgs, Shuttle Pharmaceuticals, Hempacco, Finch Therapeutics Gr, Visionary Education Tech, Marpai, Ontrak, Nogin, Adamis Pharmaceuticals, China Jo-Jo Drugstores, ABVC BioPharma, Fangdd Network Group, SeaStar Medical Holding, Yoshiharu Global, Universe Pharmaceuticals, Redhill Biopharma, Jiuzi Hldgs, Power REIT, Soligenix, Eightco Holdings, JanOne, Avalo Therapeutics, Yield10 Bioscience, Aditxt, Salarius Pharmaceuticals, China Pharma Holding, OpGen, Akanda, Harbor Custom Dev, Biocept, NeuBase Therapeutics, Ucommune International, INVO Bioscience, Esports Entertainment, American Rebel Holdings.
Portfolio Pulse from Benzinga Insights
August 11, 2023 | 6:01 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.